GAB2 has been demonstrated to act as a proto-oncogene in breast, colorectal and ovarian cancers as well as melanoma43, 44, and has been shown to be therapeutically targetable by imatinib and dasatinib45. This evidence concerns the gene GAB2 and ovarian carcinoma.